RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
PCI Biotech Holding A Stock

PCI Biotech Holding A Debt 2025

PCI Biotech Holding A Debt

-40.86 NOK

Ticker

PCIB.OL

ISIN

NO0010405640

WKN

A0Q2FS

In 2025, PCI Biotech Holding A's total debt was -40.86 NOK, a -26.8% change from the -55.83 NOK total debt recorded in the previous year.

PCI Biotech Holding A Aktienanalyse

What does PCI Biotech Holding A do?

PCI Biotech Holding ASA is a biopharmaceutical company based in Norway that focuses on the clinical development of drugs based on the so-called "Photochemical Internalization" (PCI) technology. The company was founded in 2000 as a spin-off from the Norwegian Cancer Society. The PCI technology, which is based on the use of light and chemicals to transport drugs into cells, was developed by Norwegian researchers in the 1990s. Since then, PCI Biotech has been working in collaboration with various research institutions and pharmaceutical companies to optimize this technology and advance its application in medicine. PCI Biotech's business model is based on providing its PCI technology and expertise to partners in research and industry. At the same time, the company also conducts its own clinical research on drugs based on the PCI technology. The goal is to develop drugs that are effective in various forms of cancer and other serious diseases. PCI Biotech is divided into two main divisions: the project department, which works on the development of its own drugs, and the service department, which licenses its PCI technology to third parties. One significant product of the project department is the drug "Amphinex," which is used in the treatment of pancreatic cancer. Amphinex is administered to patients in combination with chemotherapy to enhance the effectiveness of the chemotherapy. Amphinex activates the PCI technology in cancer cells, thereby facilitating the penetration of the chemotherapeutic agent into the cells. Other projects in the company's pipeline include drugs for the treatment of prostate cancer and skin cancer, as well as targeted destruction of tumor cells in the brain. The service department offers various solutions for the academic and industrial sectors. The PCI technology can be used in the development of drugs for the treatment of other diseases, such as viral infections or inflammatory diseases. Furthermore, the PCI technology can also be utilized in imaging or diagnostics. Overall, PCI Biotech is a company specialized in the development of innovative drugs. By using the PCI technology, drugs can be delivered more specifically and effectively into cells, opening up new possibilities in cancer treatment and other areas of medicine. PCI Biotech has become a significant player in clinical research in recent years and works closely with other research institutions and pharmaceutical companies to optimize their technology and explore new application areas. PCI Biotech Holding A ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding PCI Biotech Holding A's Debt Structure

PCI Biotech Holding A's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing PCI Biotech Holding A's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to PCI Biotech Holding A’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in PCI Biotech Holding A’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about PCI Biotech Holding A stock

What is the debt of PCI Biotech Holding A this year?

PCI Biotech Holding A has a debt level of -40.86 NOK this year.

What was the debt of PCI Biotech Holding A compared to the previous year?

The debt of PCI Biotech Holding A has increased by -26.8% compared to the previous year dropped.

What are the consequences of high debt for investors in PCI Biotech Holding A?

High debt can pose a risk for investors of PCI Biotech Holding A, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of PCI Biotech Holding A?

Low debt means that PCI Biotech Holding A has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from PCI Biotech Holding A affect the company?

An increase in debt of PCI Biotech Holding A can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of PCI Biotech Holding A affect the company?

A reduction in debt of PCI Biotech Holding A can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of PCI Biotech Holding A?

Some factors that can influence the debt of PCI Biotech Holding A include investments, acquisitions, operating costs, and revenue development.

Why are the debts of PCI Biotech Holding A so important for investors?

The debts of PCI Biotech Holding A are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can PCI Biotech Holding A take to change the debt?

To change the debt, PCI Biotech Holding A can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does PCI Biotech Holding A pay?

Over the past 12 months, PCI Biotech Holding A paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PCI Biotech Holding A is expected to pay a dividend of 0 NOK.

What is the dividend yield of PCI Biotech Holding A?

The current dividend yield of PCI Biotech Holding A is .

When does PCI Biotech Holding A pay dividends?

PCI Biotech Holding A pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of PCI Biotech Holding A?

PCI Biotech Holding A paid dividends every year for the past 0 years.

What is the dividend of PCI Biotech Holding A?

For the upcoming 12 months, dividends amounting to 0 NOK are expected. This corresponds to a dividend yield of 0 %.

In which sector is PCI Biotech Holding A located?

PCI Biotech Holding A is assigned to the 'Health' sector.

Wann musste ich die Aktien von PCI Biotech Holding A kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PCI Biotech Holding A from 2/27/2025 amounting to 0 NOK, you needed to have the stock in your portfolio before the ex-date on 2/27/2025.

When did PCI Biotech Holding A pay the last dividend?

The last dividend was paid out on 2/27/2025.

What was the dividend of PCI Biotech Holding A in the year 2024?

In the year 2024, PCI Biotech Holding A distributed 0 NOK as dividends.

In which currency does PCI Biotech Holding A pay out the dividend?

The dividends of PCI Biotech Holding A are distributed in NOK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von PCI Biotech Holding A

Our stock analysis for PCI Biotech Holding A Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PCI Biotech Holding A Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.